Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration

European Journal of Cancer Part A

Volumn 32, Issue 10, 1996, Pages 1734-1738

  Desoize, B ^a,b   Berthiot, G ^c   Manot, L ^a   Coninx, P ^a   Dumont, P ^c  

^a INSTITUT JEAN GODINOT   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c CHR   (France)

Author keywords

Cisplatin; Clinical Pharmacokinetics; Clinical toxicity; Dose adjustment; Etoposide

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0030249741     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00171-2     Document Type: Article

References (25)

1. 1. Grochow LB, Baraldi C, Noe D. Is dose normalisation to weight or body surface area useful in adults? Natl Cancer Inst 1990, 82, 323-325.
2. 2. Gilles E. Is dose adjustment for body surface area valid? Proc Am Assoc Cancer Res 1992, 33, 529 (Abstract).
3. 3. Reilly JJ, Workman P. Normalisation of anticancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 1993, 32, 411-418.
4. 4. Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994, 30A, 844-851.
5. 5. Kobayaschi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993, 20, 30-42.
6. 6. Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem 1993, 39, 2419-2430.
7. 7. Desoize B, Maréchal F, Millart H, Cattan A. Correlation of clinical pharmaco-kinetic parameters of cisplatin with efficacy and toxicity. Biomed Pharmacother 1991, 45, 203-207.
8. 8. Collery P, Morel M, Millart H, et al. Oral administration of gallium in conjunction with platinum in lung cancer treatment. In Collery P, Poirier LA, Manfait M, eds. Metal Ions in Biology and Medicine. London, John Libbey, 1990, Vol. 1, 437-442.
9. 9. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 1983, 67, 169-172.
10. 10. Kelsen DP, Alcock N, Young CW. Cisplatin nephrotoxicity. Correlation with plasma concentrations. Am J Clin Oncol 1985, 8, 77-80.
11. 11. Crom W, Mauer E, Greene W, et al. Relation between cisplatin ototoxicity and platinum accumulation in plasma. Proc Am Soc Clin Oncol 1984, 3, 28 (Abstract).
12. 12. Desoize B, Dumont P, Manot L, Dufour R, Berthiot G. Comparison of two dose prediction models for cisplatin. Anticancer Res 1994, 14, 2285-2290.
13. 13. Bannister SJ, Chang Y, Sternson LA, Repta AJ. Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II). Clin Chem 1978, 24, 877-880.
14. 14. Desoize B, Woirin V, Legros M, Coninx P. Reduced oral etoposide bioavailability in patients with advanced head and neck cancer. J Natl Cancer Inst 1992, 5, 348-350.
15. 15. Urien S. MicroPharm-K microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm Res 1995, 12, 1225-1230.
16. 16. Desoize B, Marechal F, Cattan A. Clinical pharmacokinetics of etoposide during 120 h continuous infusions in solid tumours. Br J Cancer 1990, 62, 840-841.
17. 17. Miller A, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
18. 18. Creagan ET, Richardson EL, Kovach JS. Pilot study of a continuous 5-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 1988, 6, 1197-1201.
19. 19. Pflüger KH, Schmidt L, Merkel M, Jungclas H, Havemann K. Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol 1987, 20, 40-66.
20. 20. McLeod HL, Santana VM, Bowman LC, Furman WL, Relling MV. Etoposide pharmacokinetics are influenced by acute but not chronic exposure to cisplatin. Proc Am Assoc Cancer Res 1992, 33, 531 (Abstract).
21. 21. Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 1994, 56, 503-511.
22. 22. Miller AA, Tolley EA, Niell HB, Stewart CF, Griffin JP. Pharmacodynamics of three daily infusion of etoposide in patients with extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol 1992, 31, 161-166.
23. 23. Joel SP, Shah R, Slevin ML. Etoposide dosage and pharmacokinetics. Cancer Chemother Pharmacol 1994, 34 (Suppl.), S69-S75.
24. 24. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapy doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993, 329, 1848-1852.
25. 25. De Vathaire F, Arriagada R, De The H, et al. Dose intensity of initial chemotherapy may have an impact on survival in limited small cell lung carcinoma. Lung Cancer 1993, 8, 301-308.